<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 09, 2023</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT05611307</url>
  </required_header>
  <id_info>
    <org_study_id>12751</org_study_id>
    <nct_id>NCT05611307</nct_id>
  </id_info>
  <brief_title>Late Subclinical Cardiovascular Disease in Testicular Cancer Survivors</brief_title>
  <official_title>Detection of Late Subclinical Cardiovascular Disease in Testicular Cancer Survivors Exposed to Cisplatin-based Chemotherapy and Bone Marrow Transplant</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Indiana University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Indiana University</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
    <is_us_export>No</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      Late subclinical cardiovascular disease in testicular cancer survivors exposed to&#xD;
      cisplatin-based chemotherapy and bone marrow transplant&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Testicular cancer (TC) is diagnosed in young adult males between 18-39 years old. There are&#xD;
      late (≥10 years after treatment) atherosclerotic cardiovascular disease (ASCVD) events after&#xD;
      cisplatin-based chemotherapy (CBCT) treatment in testicular cancer survivors (TCS), along&#xD;
      with heightened rates of hypertension, dyslipidemia, diabetes mellitus, and metabolic&#xD;
      syndrome. Early detection of ASCVD to direct preventive measures in young TCS is an unmet&#xD;
      need as these patients typically fall short of traditional 40-45-year age-cut offs for ASCVD&#xD;
      screening. ASCVD risk will be evaluated in TCS ≥ 10 years after treatment in three groups:&#xD;
      1)TCS exposed to CBCT, 2)TCS exposed to CBCT and bone marrow transplant (BMT), and 3)TCS&#xD;
      cured with surgical resection/surveillance. The focus will be on detecting subclinical&#xD;
      atherosclerosis in TCS using blood lipid biomarkers and advanced cardiac CT imaging.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">October 11, 2022</start_date>
  <completion_date type="Anticipated">December 31, 2025</completion_date>
  <primary_completion_date type="Anticipated">December 31, 2025</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Lipid profile</measure>
    <time_frame>More than 10 years after testicular cancer diagnosis, At recruitment</time_frame>
    <description>HDL, LDL, Tg, Cholesterol, Novel Lipid biomarkers using blood draws</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Coronary plaque assessment</measure>
    <time_frame>More than 10 years after testicular cancer diagnosis, At recruitment</time_frame>
    <description>Coronary calcium score, coronary artery anatomy and plaque assessment using CT scans</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Hormone levels</measure>
    <time_frame>More than 10 years after testicular cancer diagnosis, At recruitment</time_frame>
    <description>Measurement of testosterone</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Serum platinum</measure>
    <time_frame>More than 10 years after testicular cancer diagnosis, At recruitment</time_frame>
    <description>Measurement of residual serum platinum levels</description>
  </secondary_outcome>
  <number_of_groups>3</number_of_groups>
  <enrollment type="Anticipated">150</enrollment>
  <condition>Testicular Cancer</condition>
  <condition>Survivorship</condition>
  <condition>ASCVD</condition>
  <condition>Coronary Artery Disease</condition>
  <condition>Lipid Disorder</condition>
  <condition>Hypogonadism, Male</condition>
  <condition>Cisplatin Adverse Reaction</condition>
  <condition>Bone Marrow Transplant Complications</condition>
  <arm_group>
    <arm_group_label>Surgical/Surveillance</arm_group_label>
    <description>TCS cured with surgical resection and surveillance (surgical/surveillance, Arm 1)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Cisplatin-based chemotherapy (CBCT)</arm_group_label>
    <description>TCS treat with one or more lines of cisplatin-based chemotherapy</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Cisplatin-based chemotherapy and Bone Marrow Transplant (CBCT/BMT)</arm_group_label>
    <description>TCS treat with one or more lines of cisplatin-based chemotherapy, and who have undergone bone marrow transplant</description>
  </arm_group>
  <intervention>
    <intervention_type>Diagnostic Test</intervention_type>
    <intervention_name>Lipid profile</intervention_name>
    <description>Advanced lipid profile</description>
    <arm_group_label>Cisplatin-based chemotherapy (CBCT)</arm_group_label>
    <arm_group_label>Cisplatin-based chemotherapy and Bone Marrow Transplant (CBCT/BMT)</arm_group_label>
    <arm_group_label>Surgical/Surveillance</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Diagnostic Test</intervention_type>
    <intervention_name>Coronary artery assessment</intervention_name>
    <description>Coronary artery assessment via CT scans</description>
    <arm_group_label>Cisplatin-based chemotherapy (CBCT)</arm_group_label>
    <arm_group_label>Cisplatin-based chemotherapy and Bone Marrow Transplant (CBCT/BMT)</arm_group_label>
    <arm_group_label>Surgical/Surveillance</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Diagnostic Test</intervention_type>
    <intervention_name>Hormone levels for hypogonadism</intervention_name>
    <description>Hormone levels for hypogonadism</description>
    <arm_group_label>Cisplatin-based chemotherapy (CBCT)</arm_group_label>
    <arm_group_label>Cisplatin-based chemotherapy and Bone Marrow Transplant (CBCT/BMT)</arm_group_label>
    <arm_group_label>Surgical/Surveillance</arm_group_label>
  </intervention>
  <eligibility>
    <study_pop>
      <textblock>
        Testicular Cancer Patients who are disease free more than 10 years after diagnosis and&#xD;
        treatment&#xD;
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria&#xD;
&#xD;
          -  Patients &gt;18 years of age&#xD;
&#xD;
          -  Patients will be recruited only if cancer-free at clinical evaluation time.&#xD;
&#xD;
          -  For the cases a confirmed TC diagnosis who received one or more cycles of CBCT-based&#xD;
             chemotherapies (CBCT group, Arm 2)&#xD;
&#xD;
          -  For the cases with a confirmed TC diagnosis who received one or more cycles of&#xD;
             CBCT-based chemotherapies and underwent BMT for relapsed refractory disease (CBCT &amp;&#xD;
             BMT group, Arm 3).&#xD;
&#xD;
          -  For the comparison cohort, biopsy-proven TC patients who had surgery for or&#xD;
             surveillance of their testicular cancer and never received CBCTCBCT or BMT&#xD;
             (surgical/surveillance, Arm 1)&#xD;
&#xD;
        Exclusion Criteria&#xD;
&#xD;
          -  Prior known myocardial infarction (MI), atherosclerotic cardiovascular disease (ASCVD)&#xD;
&#xD;
          -  Significant renal disease (GFR&lt;40)&#xD;
&#xD;
          -  Allergy to iodinated contrast&#xD;
&#xD;
          -  Antecedent chemotherapy for another primary cancer.&#xD;
      </textblock>
    </criteria>
    <gender>Male</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>99 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Suparna C Clasen, MD MSCE</last_name>
    <role>Principal Investigator</role>
    <affiliation>Indiana University</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Suparna Clasen, MD MSCE</last_name>
    <phone>3179635462</phone>
    <email>scclasen@iu.edu</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Balaji Tamarapoo, MD PhD</last_name>
    <phone>3179635462</phone>
    <email>btamarap@iu.edu</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Indiana University</name>
      <address>
        <city>Indianapolis</city>
        <state>Indiana</state>
        <zip>46202</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Julie Lacy, RN</last_name>
      <phone>317-274-0932</phone>
      <email>julacy@iu.edu</email>
    </contact>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>November 2022</verification_date>
  <study_first_submitted>October 21, 2022</study_first_submitted>
  <study_first_submitted_qc>November 7, 2022</study_first_submitted_qc>
  <study_first_posted type="Actual">November 10, 2022</study_first_posted>
  <last_update_submitted>November 7, 2022</last_update_submitted>
  <last_update_submitted_qc>November 7, 2022</last_update_submitted_qc>
  <last_update_posted type="Actual">November 10, 2022</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Indiana University</investigator_affiliation>
    <investigator_full_name>Suparna C. Clasen</investigator_full_name>
    <investigator_title>Medical Director of Cardio-Oncology Director of Clinical Research Operations, Krannert Cardiovascular Research</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Testicular Neoplasms</mesh_term>
    <mesh_term>Cardiovascular Diseases</mesh_term>
    <mesh_term>Coronary Artery Disease</mesh_term>
    <mesh_term>Lipid Metabolism Disorders</mesh_term>
    <mesh_term>Hypogonadism</mesh_term>
    <mesh_term>Eunuchism</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Hormones</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

